Development and Validation of a Blood-Based Genomic Mutation Signature to Predict the Clinical Outcomes of Atezolizumab Therapy in NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC
Lung Cancer 2022 Aug 01;170(xx)148-155, M Liu, S Xia, X Zhang, B Zhang, L Yan, M Yang, Y Ren, H Guo, J ZhaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.